News > Jellagen signs Research Partnership Agreement with IFREMER – The French Institute of Research and Marine Exploitation

Jellagen signs Research Partnership Agreement with IFREMER – The French Institute of Research and Marine Exploitation

12/04/21

 

  • Partnership agreement enables Jellagen privileged access to Ifremer’s proprietary technology on testing new marine derived natural products for medical research.
  • The agreement grants Jellagen a first option to acquire an exclusive world-wide license to commercialise Ifremer technology combined with Jellagen biomaterials for medical applications.

Jellagen®, a medical device and biotechnology development company manufacturing high value Collagen Type 0 biomaterial derived from jellyfish is delighted to announce the signing of a new Partnership Agreement with the world renowned French Institute of Research and Marine Exploitation, IFREMER.

The agreement allows Jellagen privileged access to Ifremer specific and proprietary marine derived natural product technology, some bacterial polysaccharides endowed with glycosaminoglycan-like properties, supporting Jellagen’s R&D in the field of creating new and innovative medical devices.

Ifremer is recognized throughout the world as one of the very first institutes in marine science and technologies. Ifremer’s focus has a dual perspective of both sustainable development and open science. It conducts research, produces expertise and creates innovations to protect and restore the ocean, use its resources responsibly, share marine data and offer new services to all stakeholders.

Jellagen’s Chief Executive Officer, Mr Thomas-Paul Descamps stated:

“Marine biotechnology offers great potential for the discovery and development of truly new chemistry and medical innovation from the sustainable use of marine resources.   We are therefore delighted to have entered into this research partnership and are excited to begin the evaluation of a novel marine natural product technology, to advance Jellagen’s key medical development programmes.” 

Dr. Sylvia Colliec-Jouault of Ifremer’s Laboratory of Microbial Ecosystem and Marine Molecules for Biotechnologies also stated:

“Jellagen’s expertise linked to Ifremer research presents a great opportunity for the development of innovative biomaterials totally composed of marine biomolecules. This partnership is a nice demonstration that ocean exploration may serve medical fields by offering a tremendous resource for the discovery of new bioactive molecules.”

About Ifremer

A pioneer in ocean science, IFREMER’s cutting-edge research is grounded in sustainable development and open science. Our vision is to advance science, expertise and innovation to:

– Protect and restore the ocean

– Sustainably use marine resources to benefit society

– Create and share ocean data, information & knowledge.

With more than 1,500 personnel spread along the French coastline in more than 20 sites, the Institute explores the 3 great oceans: the Indian, Atlantic and Pacific oceans. A leader in ocean science, IFREMER is managing the French Oceanographic Fleet. Well-established in the international scientific community, our scientists, engineers and technicians are committed to advance knowledge about our planet’s last unexplored frontiers.


For more information please contact:

Adam Watts, Digital Marketing Manager, Jellagen

T: +44 (0) 3333 583 299

www.jellagen.co.uk

Aurelie Lecolier, Division of partnerships and transfer for Innovation, Ifremer

Aurelie.Lecolier@ifremer.fr

 

Download the press release here.